Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.60 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.57 |
| ▸ | LPAR3 | Q9UBY5 | 7/20 | 0.57 |
| ▸ | LPAR2 | Q9HBW0 | 4/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.56 |
| ▸ | CNR1 | P21554 | 1/20 | 0.56 |
| ▸ | CNR2 | P34972 | 1/20 | 0.56 |
| ▸ | TLR2 | O60603 | 2/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.48 |
| ▸ | DNM1 | Q05193 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | LPAR6 | P43657 | 3/20 | 0.46 |
| ▸ | LPAR4 | Q99677 | 3/20 | 0.46 |
| ▸ | LPAR5 | Q9H1C0 | 3/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2523306 | 1.00 | USP2 (0.60) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL1083230 | 1.00 | USP2 (0.60) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL15016340 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7058701 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7063486 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL25266425 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL2417250 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL103054 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL10561321 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 | |
| SCHEMBL7063456 | 0.98 | USP2 (0.63) | USP2LPAR1LPAR3LPAR2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 545 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002430-A1 | METHOD FOR PRODUCING PROTEIN COMPOSITIONS | HOFFMAN-LA ROCHE INC. (US) | 2024-01-04 | — | — | US | claimed |
| US-11834694-B2 | Structural lipids | PLANTED FOODS AG (CH) | 2023-12-05 | — | — | US | claimed |
| WO-2023148208-A1 | GAS LOSS REDUCING ADDITIVE FOR BEVERAGES, A BEVERAGE COMPOSITION INCLUDING THE GAS LOSS REDUCING ADDITIVE AND A METHOD OF REDUCING GAS LOSS FROM A BEVERAGE | GIVAUDAN SA (CH) | 2023-08-10 | — | — | WO | claimed |
| US-20230057409-A1 | STRUCTURAL LIPIDS | PLANTED FOODS AG (CH) | 2023-02-23 | — | — | US | claimed |
| US-20190195897-A1 | GLYCOSYLATED METABOLITES | UNIVERSITEIT LEIDEN (NL) | 2019-06-27 | — | — | US | claimed |
| EP-2809789-B1 | ENZYMATIC PROCESS FOR FAT HYDROLYSIS IN A POLAR ORGANIC SOLVENT | LALI ARVIND MALLINATH (IN) | 2018-09-12 | — | — | EP | claimed |
| EP-2709462-B1 | OIL OR FAT COMPOSITIONS CONTAINING DIGLYCERIDES | KAO CORP (JP) | 2017-02-22 | — | — | EP | claimed |
| US-9512451-B2 | Enzymatic process for fat and oil hydrolysis | INSTITUTE OF CHEMICAL TECHNOLOGY (DEEMED UNIVERSITY) (IN) | 2016-12-06 | — | — | US | claimed |
| EP-2173325-B1 | Cyclic somatostatin slow-release formulations | CAMURUS AB (SE) | 2016-10-19 | — | — | EP | claimed |
| EP-2579844-B1 | NANOPARTICLE FILM DELIVERY SYSTEMS | MIDATECH LTD (GB) | 2016-02-24 | — | — | EP | claimed |
| WO-2003069997-A1 | IMMUNOSTIMULANT COMPOSITIONS COMPRISING AMINOALKYL GLUCOSAMINIDE PHOSPHATES AND SAPONINS | CORIXA CORPORATION (US) | 2003-08-28 | — | — | WO | claimed |
| EP-0996451-A4 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS INC (US) | 2001-04-18 | — | — | EP | claimed |
| US-6080725-A | COMPRISING ONE OR MORE BACTERIAL, VIRAL OR TUMOR-ASSOCIATED ANTIGENS; AND ONE OR MORE SAPONIN-LIPOPHILE CONJUGATE | GALENICA PHARMACEUTICALS, INC. (US) | 2000-06-27 | — | — | US | claimed |
| EP-0996451-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | Galenica Pharmaceuticals, Inc. (US) | 2000-05-03 | — | — | EP | claimed |
| US-5977081-A | PLANT EXTRACT; ADJUST IMMUNOLOGY RESPONSE | GALENICA PHARMACEUTICALS, INC. (US) | 1999-11-02 | — | — | US | claimed |
| WO-1998052573-A1 | TRITERPENE SAPONIN ANALOGS HAVING ADJUVANT AND IMMUNOSTIMULATORY ACTIVITY | GALENICA PHARMACEUTICALS, INC. (US) | 1998-11-26 | — | — | WO | claimed |
| EP-0658629-A1 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1995-06-21 | — | — | EP | claimed |
| EP-0207252-B1 | AROMATIC HYDROXY- OR THIOL DERIVATIVES OF CARBONIC-ACID ESTERS AS LIPASE SUBSTRATES | Roche Diagnostics GmbH (DE) | 1992-07-29 | — | — | EP | claimed |
| WO-1990009981-A1 | PREPARATION OF OPTICALLY ACTIVE GLYCEROL DERIVATIVES | ISIS INNOVATION LIMITED (GB) | 1990-09-07 | — | — | WO | claimed |
| EP-0319126-A2 | Process for preparation of polyol fatty acid ester and glyceride mixture obtained | Kao Corporation (JP) | 1989-06-07 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190195897-A1 | GLYCOSYLATED METABOLITES | UGCG, GBA1, GBA2 | USP2 3555/4885LPAR1 2206/4885LPAR3 1973/4885 |
| US-20240002430-A1 | METHOD FOR PRODUCING PROTEIN COMPOSITIONS | CETP, IDE, LIPA | USP2 75/4885LPAR1 1405/4885LPAR3 1655/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.